Qingdao Haier Biomedical Co., Ltd. has reported its 2025 annual results, revealing a continued pattern of revenue growth without corresponding profit increases. The company announced revenue of 2.329 billion yuan, representing a slight increase of 1.96% year-over-year. However, net profit attributable to shareholders plummeted by 31.61% to 251 million yuan.
This marks the fourth consecutive year of declining profits for the biomedical storage specialist. The current net profit level represents only approximately 30% of the company's 2021 peak performance.
During the fourth quarter specifically, revenue reached 567 million yuan, up 13.09% compared to the same period last year. Despite this revenue growth, quarterly net profit declined by 8.96% to 52 million yuan.
Company management attributed the profit pressure to multiple factors including complex international trade relations, ongoing industry demand recovery, production ramp-up at new facilities, and increased strategic investments for long-term growth.
The company's stock closed at 31.21 yuan per share on March 31, representing a decline of nearly 80% from its historical peak, with a current market capitalization of approximately 9.878 billion yuan.
While domestic revenue decreased by 5.5% to 1.47 billion yuan in 2025, international business emerged as a bright spot with overseas revenue growing 17.9% to 840 million yuan. International operations now account for 36% of total revenue, up 5 percentage points from 2024.
Looking forward, the company has established an ambitious three-year "543" strategic target: overseas revenue contribution exceeding 50%, acquisition-related revenue exceeding 40%, and AI-related revenue contribution reaching 30%.
In corporate governance developments, the company has appointed Liu Gang as co-CEO, marking the implementation of a dual-CEO leadership structure alongside current CEO Liu Zhanjie.
Since its listing in 2019, the company has maintained consistent dividend payments, distributing a cumulative total of 891 million yuan in cash dividends with a payout ratio of 29.38%. For the 2026-2028 period, the company has committed to distributing no less than 10% of distributable profits as annual dividends.
CEO Liu Zhanjie, who transitioned from academic research to entrepreneurship, received total compensation of 2.2707 million yuan in 2025. Historical records indicate his indirect shareholding of approximately 10.12 million shares, which would have generated nearly 38 million yuan in cumulative dividends assuming no share sales since listing.
Comments